Hemostatic Disorders
Welcome,         Profile    Billing    Logout  
 199 Companies   329 Products   329 Products   164 Mechanisms of Action   13 Trials   3303 News 


12345678910111213...6768»
  • ||||||||||  simvastatin / Generic mfg.
    Trial termination:  Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins (clinicaltrials.gov) -  Mar 12, 2024   
    P1,  N=12, Terminated, 
    Phase classification: P1/2 --> P1 Completed --> Terminated; Research was completed before January 18, 2017, & does not meet the Applicable Clinical Trial requirement to register & report results per the guidance provided in "Clinical Trials Registration & Results Information Submission" dated 09/21/2016.
  • ||||||||||  dexamethasone / Generic mfg., bendamustine / Generic mfg., pomalidomide / Generic mfg.
    Trial completion date:  Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (clinicaltrials.gov) -  Feb 20, 2024   
    P1/2,  N=56, Active, not recruiting, 
    Completed --> Terminated; Research was completed before January 18, 2017, & does not meet the Applicable Clinical Trial requirement to register & report results per the guidance provided in "Clinical Trials Registration & Results Information Submission" dated 09/21/2016. Trial completion date: Jan 2023 --> Jan 2025
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Phase classification, Combination therapy:  Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) -  Jan 24, 2024   
    P1,  N=3, Terminated, 
    Trial completion date: Jan 2023 --> Jan 2025 Phase classification: P1/2 --> P1
  • ||||||||||  lenalidomide / Generic mfg.
    Trial completion, Trial completion date:  IFM2005-02: Maintenance Therapy Using Lenalidomide in Myeloma (clinicaltrials.gov) -  Apr 26, 2019   
    P3,  N=614, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Sep 2018
  • ||||||||||  bortezomib / Generic mfg.
    Trial completion:  Bortezomib Consolidation Trial (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=40, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  bortezomib / Generic mfg.
    Trial completion:  Autophagy Induction After Bortezomib for Myeloma (clinicaltrials.gov) -  Apr 20, 2019   
    P1,  N=11, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018 Active, not recruiting --> Completed
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) -  Apr 2, 2019   
    P=N/A,  N=23, Terminated, 
    Active, not recruiting --> Completed | N=26 --> 18 N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data.
  • ||||||||||  Trial completion, HEOR:  PSY_HaEMOPEQ: Effectiveness of Psychological Interventions in Haemophilia (clinicaltrials.gov) -  Mar 26, 2019   
    P=N/A,  N=20, Completed, 
    N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. Active, not recruiting --> Completed
  • ||||||||||  staphylococcal protein A (PRTX-100) / Protalex
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) -  Mar 25, 2019   
    P1b,  N=15, Terminated, 
    Active, not recruiting --> Completed N=30 --> 15 | Trial completion date: Dec 2018 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Enough data has been collected to allow analysis of the safety profile and risk-benefit.
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Trial completion date, Trial termination, Trial primary completion date:  Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients (clinicaltrials.gov) -  Mar 18, 2019   
    P2,  N=24, Terminated, 
    N=30 --> 15 | Trial completion date: Dec 2018 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Enough data has been collected to allow analysis of the safety profile and risk-benefit. Trial completion date: Jun 2020 --> Jun 2017 | Active, not recruiting --> Terminated | Trial primary completion date: May 2019 --> May 2017; retirement of PI
  • ||||||||||  bortezomib / Generic mfg.
    Trial completion, Enrollment change:  Evaluation of Cardiotoxic Effects of Bortezomib (clinicaltrials.gov) -  Mar 14, 2019   
    P=N/A,  N=11, Completed, 
    Active, not recruiting --> Terminated; lack of recruitment Not yet recruiting --> Completed | N=20 --> 11
  • ||||||||||  samalizumab (ALXN 6000) / The Leukemia & Lymphoma Society, AstraZeneca
    Trial termination:  Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM (clinicaltrials.gov) -  Mar 5, 2019   
    P1/2,  N=26, Terminated, 
    Recruiting --> Completed Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns.
  • ||||||||||  Trial completion, Trial completion date, Combination therapy:  ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) -  Mar 1, 2019   
    P2,  N=35, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2018
  • ||||||||||  Trial completion, Trial completion date:  Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) -  Feb 20, 2019   
    P=N/A,  N=19, Completed, 
    N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections. Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Aug 2017
  • ||||||||||  Biomarker, Enrollment change, Trial withdrawal:  The Role of Microparticles as a Biomarker (clinicaltrials.gov) -  Feb 19, 2019   
    P=N/A,  N=0, Withdrawn, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Aug 2017 N=200 --> 0 | Enrolling by invitation --> Withdrawn
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Individualizing Hemophilia Prophylaxis Using Thromboelastography (clinicaltrials.gov) -  Feb 18, 2019   
    P=N/A,  N=18, Completed, 
    N=200 --> 0 | Enrolling by invitation --> Withdrawn Recruiting --> Completed | N=60 --> 18 | Trial completion date: Dec 2018 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Dec 2017
  • ||||||||||  Enrollment closed:  HeL-Fascial: Fascial Therapy in Elbow Hemophilic Arthropathy (clinicaltrials.gov) -  Feb 6, 2019   
    P=N/A,  N=60, Active, not recruiting, 
    Recruiting --> Completed | N=60 --> 18 | Trial completion date: Dec 2018 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Dec 2017 Recruiting --> Active, not recruiting
  • ||||||||||  Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
    Trial completion, Trial completion date, Trial primary completion date:  SHIVERING 2: Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (clinicaltrials.gov) -  Jan 30, 2019   
    P2,  N=122, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jun 2018 | Trial primary completion date: Dec 2016 --> Oct 2017
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  MRA With Feraheme in HHT (clinicaltrials.gov) -  Jan 25, 2019   
    P1,  N=10, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jun 2018 | Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Completed | Trial completion date: Nov 2017 --> Nov 2018 | Trial primary completion date: Nov 2017 --> Nov 2018
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  MCSF-MYELOME: Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma (clinicaltrials.gov) -  Jan 23, 2019   
    P=N/A,  N=111, Completed, 
    Recruiting --> Completed | Trial completion date: Nov 2017 --> Nov 2018 | Trial primary completion date: Nov 2017 --> Nov 2018 Recruiting --> Completed | N=200 --> 111 | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018
  • ||||||||||  Trial termination:  GERMAIN: Treatment Optimization in Patients With Untreated Multiple Myeloma (clinicaltrials.gov) -  Jan 16, 2019   
    P2/3,  N=85, Terminated, 
    Active, not recruiting --> Completed | N=22 --> 32 | Trial completion date: Dec 2018 --> Apr 2017 Active, not recruiting --> Terminated; Insufficient recruitment
  • ||||||||||  everolimus / Generic mfg., bendamustine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) -  Jan 4, 2019   
    P1,  N=20, Completed, 
    Active, not recruiting --> Terminated; Insufficient recruitment Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018
  • ||||||||||  Enrollment change, Trial withdrawal:  KAPPA: Key Aspects of Medical Practice in Patients With Haemophilia A (clinicaltrials.gov) -  Dec 22, 2018   
    P=N/A,  N=0, Withdrawn, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018 N=1000 --> 0 | Enrolling by invitation --> Withdrawn
  • ||||||||||  Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Correlative Biomarker Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) -  Dec 13, 2018   
    P=N/A,  N=592, Completed, 
    Trial completion date: Jun 2014 --> Oct 2018 Recruiting --> Completed | N=860 --> 592 | Trial completion date: Jun 2019 --> Jul 2018 | Trial primary completion date: Jun 2019 --> Jul 2018
  • ||||||||||  Kinaction (masitinib) / AB Science
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy:  A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (clinicaltrials.gov) -  Dec 5, 2018   
    P3,  N=147, Terminated, 
    N=25 --> 8 | Recruiting --> Terminated; low enrollment N=300 --> 147 | Trial completion date: Dec 2014 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2013 --> Jun 2018; Sponsor decision based on portfolio prioritization